Is tamoxifen used for ER-positive breast cancer?

Adjuvant therapy for early-stage breast cancer: Tamoxifen is FDA approved for adjuvant hormone treatment of premenopausal and postmenopausal women (and men) with ER-positive early-stage breast cancer, and the aromatase inhibitors anastrozole, letrozole, and exemestane are approved for this use in postmenopausal women.

What is survival rate for ER-positive breast cancer?

Breast cancer survival at 15 years was 77% for women with ER-positive tumors and 70% for women with ER-negative tumors. ¶ Overall survival at 10 years was 77% for women with ER-positive tumors and 68% for women with ER-negative tumors.

Does ER-positive breast cancer come back?

The risk for recurrence of ER-positive breast cancers persists for a prolonged period, with approximately 50% of recurrences occurring 5 years after initial diagnosis. Results of several randomized trials suggest that extending adjuvant endocrine treatment beyond 5 years can improve disease-free survival (DFS).

Is tamoxifen better than chemotherapy?

At a median follow-up of 5 years tamoxifen appeared to be more effective than chemotherapy, the difference being highly significant in postmenopausal women. The addition of chemotherapy to tamoxifen was not able to significantly improve the results achieved by tamoxifen alone, irrespective of menopausal status.

Is ER positive breast cancer slow growing?

Hormone receptor-positive cancers tend to grow more slowly than those that are hormone receptor-negative. Women with hormone receptor-positive cancers tend to have a better outlook in the short-term, but these cancers can sometimes come back many years after treatment.

Is ER positive breast cancer curable?

ER-positive breast cancer has a high chance of being successfully treated, especially when it’s discovered early. A diagnosis at a later stage will have a less positive outlook, but being diagnosed at a later stage is less common. There are still many treatment options for late stage cancer.

Is estrogen positive breast cancer more likely to recur?

Studies have shown that estrogen-receptor-positive breast cancer has a more drawn-out risk of recurrence compared to estrogen-receptor-negative disease. About 50% of estrogen-receptor-positive breast cancer recurrences happen 5 or more years after the initial diagnosis.

Will tamoxifen make my hair fall out?

It’s not only chemotherapy that causes breast cancer patients to lose their hair. Treatment with endocrine therapy (ie, tamoxifen or an aromatase inhibitor) can also cause hair loss and have a negative impact on quality of life, even when the loss is only mild in severity, a novel study suggests.

Is it better to have ER positive or negative breast cancer?

The survival rate for breast cancers are excellent if the cancer is detected early, and in general HR positive cancers grow slower and have a better prognosis. Overall, breast cancers that are both HR positive and HER2 negative have the best outcomes.

Is ER positive breast cancer aggressive?

The estrogen activation of ER in ER-positive breast cancers enhances their aggressiveness, while the activation of exogenously introduced ERs into aggressive ER-negative cells diminishes their aggressiveness.

How do you prevent estrogen positive breast cancer recurrence?

After surgery, most women diagnosed with estrogen-receptor-positive breast cancer take hormonal therapy medicine to reduce the risk of recurrence. There are several types of hormonal therapy medicines. Tamoxifen, a selective estrogen receptor modulator (SERM), is one of the most well-known.

Does tamoxifen cause GREY hair?

Tamoxifen, a widely used selective oestrogen receptor modulator, SERM, was described occasionally in medical case reports as causing grey hair repigmentation.

Can tamoxifen cause belly fat?

Tamoxifen users had more visceral adipose tissue (VAT) and more liver fat than controls. This is the first study to demonstrate that fatty liver and intra-abdominal fat accumulation are common in breast cancer patients receiving tamoxifen.